Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai to introduce Crystal Veil Cool
According to Eisai, Crystal Veil can be used as a preventative measure against airborne allergens such as pollen and house dust by applying a single drop the size
According to Eisai, Crystal Veil can be used as a preventative measure against airborne allergens such as pollen and house dust by applying a single drop the size
Nutra Pharma is expected to use the grant proceeds to support additional clinical work on its pain treatments. Nutra Pharma chairman and CEO Rik Deitsch said that it
Aceto has posted a net income of $2.8m for the first quarter 2010, or $0.11 per diluted share, compared to $1m, or $0.04 per diluted share, for the
PV-10 is a proprietary, injectable formulation of Rose Bengal, a small molecule agent that has been in use for nearly 30 years by ophthalmologists to assess damage to
American Regent has initiated the voluntary recall because some vials of this lot were observed to be slightly discolored and upon standing have the appearance of sediment on
Celanese claims that VitalDose excipients are based on EVA polymers and offer a wide degree of flexibility in the design of transdermal, subcutaneous implant and mucosal insert dosage
Horizant, also referred to as GSK1838262/XP13512, is a patented new chemical entity. It is under review for the treatment of moderate-to-severe primary restless legs syndrome (RLS). FDA has
Vilazodone is a novel dual-acting modulator of serotonin neurotransmission in development for the treatment of major depressive disorder with the potential for follow-on indications including generalised anxiety disorder
Utilising CTMS as a centralised repository for all investigators, clinical trial sponsors can collect and track all relevant information about their investigators, from personal profiles to disease specialties,
Reportedly, a mean Progression Free Survival (PFS) of 11.7 months was observed among subjects achieving an OR. In the PV-10 Phase 2 trial, a complete response (CR) of